Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 35
Filter
1.
Aerosol Science and Engineering ; 2023.
Article in English | Scopus | ID: covidwho-2304751

ABSTRACT

The rapid growth of urban areas and population as well as associated development over recent decades have been a major factor controlling ambient air quality of the urban environment in Kerala (India). Being located at the southwestern fringe of the Indian peninsula, Kerala is one of the regions that has been significantly influenced by the activities in the Indian Ocean. The present study focuses on the effect of the COVID-19 lockdown (in 2021) on ambient air quality in the selected coastal metropolitan areas of Kerala. Although previous research studies reported improvement in ambient air quality in Kerala during the lockdown period, this study demonstrates the potential of onshore transport of air pollutants in controlling the air quality of coastal urban regions during the lockdown period. Data from the ambient air quality monitoring stations of the Kerala State Pollution Control Board in the urban areas of Thiruvananthapuram (TM), Kollam (KL), Kozhikode (KZ), and Kannur (KN) are used for the analysis. Temporal variation in the concentration of air pollutants during the pre-lockdown (PRLD), lockdown (LD), and post-lockdown (PTLD) periods (i.e., 1 March to 31 July) of 2021 is examined to assess the effect of lockdown measures on the National Air Quality Index (AQI). Results indicate a significant decline in the levels of air pollutants and subsequent improvement in air quality in the coastal urban areas. All the effect of lockdown measures has been evident in the AQI, an increase in the concentration of different pollutants including CO, SO2, and NH3 during the LD period suggests contributions from multiple sources including onshore transport due to marine traffic and transboundary transport. © 2023, The Author(s) under exclusive licence to Institute of Earth Environment, Chinese Academy Sciences.

2.
Journal of Heart & Lung Transplantation ; 42(4):S318-S318, 2023.
Article in English | Academic Search Complete | ID: covidwho-2270517

ABSTRACT

The COVID-19 pandemic drove a sustained increase in the volume and duration of venovenous extracorporeal membrane oxygenation (VV-ECMO), accelerating a decade long trend. While current clinical consensus recommends a maximal support duration of 14-21 days, the observed change in practice may warrant revisiting this notion. To guide this, we describe our institution's experience with prolonged VV-ECMO support. We performed a retrospective cohort analysis of patients who received VV-ECMO support at a large academic medical center between 2018-2022 using medical records. This study is a descriptive report of patients who received prolonged VV-ECMO support, defined as >50 continuous days on circuit. Of the 130 patients who received VV-ECMO during the study period, 12 (9.2%) had a support duration of >50 days, 11 of whom suffered from adult respiratory distress syndrome (ARDS) secondary to COVID-19, while 1 patient with prior bilateral lung transplant suffered from ARDS secondary to bacterial pneumonia. The median duration of VV-ECMO support was 94 days [IQR: 69.5, 128], with a maximum support of 180 days. Median time from intubation to cannulation was 5 days [IQR: 2, 14]. On-circuit mobilization was performed in 9 patients (75%). Successful weaning of VV-ECMO support occurred in 8 patients (67%), with 6 (50%) bridged to lung transplantation and 2 (17%) bridged to recovery. A total of 7 patients (58%) were discharged from the hospital: 3 to home and 4 to a rehabilitation center. ECMO complications included cannulation site bleeding in 10 patients (83%), gastrointestinal bleeding in 4 patients (33%), oxygenator failure in 7 patients (58%), and required circuit exchanges in 9 patients (75%) (Figure 1). Extremely prolonged VV-ECMO support allows for successful recovery or optimization of lung transplant candidacy in a select group of patients at a high-volume institution, further supporting the expanded utilization of VV-ECMO. [ABSTRACT FROM AUTHOR] Copyright of Journal of Heart & Lung Transplantation is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

3.
Journal of Heart & Lung Transplantation ; 42(4):S102-S103, 2023.
Article in English | Academic Search Complete | ID: covidwho-2284020

ABSTRACT

We evaluated the impact of a 6-8 cm minimally invasive (mini-) incision (Figure-A) on early outcomes after lung transplantation (LTx) compared to traditional incisions An institutional registry identified 37 mini-LTx and 106 traditional access (42 clamshells, 48 thoracotomies, 16 sternotomies) LTx patients (01/2017-06/2022), after excluding repeat/multiorgan transplants and those with COVID-19 acute respiratory distress syndrome who required pre-transplant extracorporeal membrane oxygenation (n=27). Propensity score matching by age, sex, body mass index, diagnosis, lung allocation score (LAS), double vs. single lung, hypertension, diabetes, and hospitalization status created 37 pairs Before matching, mini-LTx patients had similar LAS (39.2 [IQR 36.6-45.9] vs 41.1 [IQR 34.9-48.0]) compared to traditional LTx cohorts (both p>0.05). After matching, there was no difference between mini- and traditional LTx cohorts in warm ischemic time (66 [IQR 60-81] vs 62 [IQR 54-84] mins). Operative time was numerically shorter in mini-LTx patients for both double (399 [IQR 369-455] vs. 441 [IQR 373-545] mins, p=0.17) and single lung LTx (240 [IQR 208-272] vs. 272 [187-289] mins, p=0.57). After LTx, Mini-LTx was associated with similar mechanical ventilation duration (25.5 [IQR 19.5-38.7] vs 28.7 [IQR 19.0-69.5] hours, p=0.26), numerically lower rate of grade 3 primary graft dysfunction at 72 hours (3 vs. 15%, p=0.10), and shorter ICU and hospital length of stay (Figure-B). Among matched patients who survived to discharge, mini-LTx patients required less opiates prescription at discharge (38 vs 66%, p=0.02), and had improved pulmonary function at 3 months (FEV1 82 [IQR 72-102] vs 77 [52-88] % predicted;FVC 78 [IQR 65-92] vs 70 [IQR 62-80] % predicted;both p<0.05). In selected patients, LTx using a minimally invasive incision is safe with improved postoperative pulmonary function, shorter length of stay, and reduced outpatient opiate use. [ABSTRACT FROM AUTHOR] Copyright of Journal of Heart & Lung Transplantation is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

4.
Medical Journal of Dr DY Patil Vidyapeeth ; 15(8):345-347, 2022.
Article in English | Scopus | ID: covidwho-2202081

ABSTRACT

Sixty-five-year old man, known hypertensive with previous history of cerebrovascular accident presented to the Emergency Department with complaints of acute onset ptosis for the last 7 h. Onset of ptosis was sudden and was not associated with waxing and waning of symptoms. Examination revealed bilateral ptosis with no other neurological deficits. Differentials of acute cerebrovascular accident, myasthenia, and neurotoxic envenomation were considered. Magnetic resonance imaging stroke protocol was done which revealed an acute mid brain infarct. Real-time polymerized chain reaction test for corona virus disease 19 (COVID-19) done in view of the pandemic situation was positive. Acute onset bilateral ptosis is an infrequent presentation to any emergency room. Prompt diagnosis and evaluation of the various differentials is of utmost significance in improving the patient outcome. Ptosis occurs due to paresis of levator palpebrae superioris (LPS) and Mullers muscle. In this patient, isolated ptosis with papillary sparing probably occurs due to the involvement of caudal sub nucleus of oculomotor nucleus. Ischemic events especially stroke is emerging as complication of COVID-19. COVID-19 is associated with hypercoagulopathy and the elevation of d-dimer and fibrinogen, leading to potential complications like acute stroke. COVID-19 infection may not always present with the typical respiratory symptoms and atypical presentations are incrementing. However, the patient had risk factors for stroke and a causal relationship with coronavirus infection remains conjectural. © 2022 Medical Journal of Dr. D.Y. Patil Vidyapeeth ;Published by Wolters Kluwer - Medknow.

5.
International Conference on Information Systems and Intelligent Applications, ICISIA 2022 ; 550 LNNS:465-476, 2023.
Article in English | Scopus | ID: covidwho-2148567

ABSTRACT

The pandemic of Covid-19 has changed the lifestyle of people nowadays. Students has to adapt to the new norms in which they need to rely on the digital mediums to interact with others. The main purpose of this study is to investigate the relationship between social media use and the connectedness among the university students in Malaysia during this pandemic of Covid-19. It also aims to investigate connection between the purposes of social media use (academic, socialization, entertainment and informativeness) and the level of social connectedness. Thirdly, the genders difference between social media use and social connectedness are investigated. The measurement used include the online social networking usage questionnaire and the social connectedness scale, and were distributed through snowball sampling method via the online platforms. A total of 300 respondents were recruited in this study with the mean age of 22.26. The results indicate that no significant relationship between social media usage and social connectedness. However, there was significant relationship between the purposes of using social media and social connectedness. Thirdly, no difference was found between females and males on the social media usage and social connectedness. Finally, this study highlights that the purpose of using social media could enhance the social relationship. © 2023, The Author(s), under exclusive license to Springer Nature Switzerland AG.

7.
Annals of Oncology ; 33(Supplement 9):S1528-S1529, 2022.
Article in English | EMBASE | ID: covidwho-2129911

ABSTRACT

Background: Managing head and neck squamous cell carcinoma (HNSCC) requires a prolonged course of concurrent chemoradiotherapy and other supportive care measures. Such a multidisciplinary approach was significantly hampered during the emergence of the COVID-19 pandemic which necessitated divergence of health resources towards treating the infected patients thereby compromising cancer care. Therefore, we adopted an alternate-day hypofractionated radiotherapy (ADH RT) schedule, aiming to decrease patients' hospital visits daily without compromising the oncological outcomes. This study assesses the response and toxicity of the ADH RT schedule in HNSCC patients. Method(s): Retrospective analysis of all histopathologically proven HNSCC patients treated with ADH RT regimen during April - October 2020 in our institute. Hypofractionation dose schedule: 63Gy/21 fractions, 3Gy/fraction was delivered on alternate days without concurrent chemotherapy after patients' consent. Weekly radiation toxicity assessment and post-radiotherapy response assessment by CECT face and neck at 3 and 6 months. Result(s): A total of 26 patients were planned for ADH RT. Most (96%) of them were males with a median age of 60 years and ECOG PS <=2. The most common tumor site was the oropharynx (58%), the stage was IVA (54%) followed by stage IVB (27%). 93% of patients had a history of tobacco smoking. Only 23 patients completed the treatment and were included in the final assessment. Mucositis and dermatitis grade 1, 2 and 3 was observed in 44%, 52%, 4% and 78%, 18%, and 4% patients, respectively. At three months of follow-up, 5 patients were lost to follow-up and 4 patients expired due to COVID/disease-related complications. Complete response (CR) was observed in 10 patients (71.4%) and partial response in 4 patients. At 6 months, CR was observed in 7 (64.5%) patients. Conclusion(s): Most of the patients were able to tolerate and complete treatment. At analysis, around half of the patients either expired or were lost to follow-up which is the major limitation of this study. Among the available patients, a good response was observed. The practical applicability of this regimen needs to be tested further with a larger sample size and longer follow-up. Legal entity responsible for the study: The authors. Funding(s): Has not received any funding. Disclosure: All authors have declared no conflicts of interest. Copyright © 2022

9.
Trends in Biomaterials and Artificial Organs ; 36(2):121-123, 2022.
Article in English | Scopus | ID: covidwho-2011524

ABSTRACT

The COVID-19 pandemic started by the SARS-CoV-2 virus from China hit different parts of the world and caused till now the first, second and third waves at different time periods from March 2020 to December 2021. Virus variants emerged to cause these waves with altered behaviour and severity of the disease and difficulty in the management of the pandemic. An unexpected upsurge happened during these waves due to social reasons and policies. In this article, we discuss the variations in the waves from a few geographic locations which will give us a better understanding of regional effects and precautions needed for the future. © 2022 Society for Biomaterials and Artificial Organs - India. All rights reserved.

10.
11.
Indian Journal of Law and Justice ; 13(1):364-385, 2022.
Article in English | Scopus | ID: covidwho-1940069

ABSTRACT

Patent pools covers agreements whereby two or more parties agree to pool their respective technologies and license them as a package. It facilitates public health management of IP through a partnership between an entity with a public health mandate on one hand and private pharmaceutical companies on the other hand. This model of access-oriented and nonexclusive voluntary licensing mechanisms with a clear public health mandate can contribute to achieving this goal of Universal Health coverage and can overcome a number of access and innovation challenges in the biopharmaceutical field. This can be substantiated by analyzing the successful Medicines Patent pool. The benefits of collaborative research and an efficient patent pool could also be witnessed when COVID-19 pandemic was declared as a Public Health Emergency of International Concern by the World Health Organization (WHO) on January 30, 2020, where they launched the COVID-19 Technology Access Pool (C-TAP) with a Solidarity Call to Action for sharing intellectual property on treatments and vaccines. © 2022, Department of Law, University of North Bengal. All rights reserved.

12.
HemaSphere ; 6(SUPPL 2):16-17, 2022.
Article in English | EMBASE | ID: covidwho-1915867

ABSTRACT

G protein-coupled receptor family C group 5 member D (GPRC5D) has limited expression in healthy human tissue but is highly expressed in malignant plasma cells, making it a promising target for immunotherapy approaches for MM. Talquetamab (JNJ-64407564) is a first-in-class bispecific antibody that binds to both GPRC5D and CD3 receptors to redirect T cells to kill MM cells. Updated and new results of talquetamab at the recommended phase 2 doses (RP2Ds) are reported (NCT03399799). Eligible patients had RRMM or were intolerant to standard therapies. Patients who were previously treated with B-cell maturation antigen (BCMA)-directed therapies were eligible. This analysis focuses on patients who received talquetamab subcutaneously (SC;range: 5.0-800 μg/kg) weekly (QW) or biweekly (Q2W) with step-up dosing. The primary objectives were to identify the RP2D (part 1) and assess talquetamab safety and tolerability at the RP2Ds (part 2). Adverse events (AEs) were graded by CTCAE v4.03;cytokine release syndrome (CRS) was graded per Lee et al 2014 criteria. Responses were investigator-assessed per IMWG criteria. As of July 19, 2021, 95 patients had received SC talquetamab. The original RP2D was 405 μg/kg SC talquetamab QW with step-up doses, and a second RP2D of 800 μg/kg SC talquetamab Q2W with step-up doses was also identified. 30 patients received 405 μg/kg QW (median 61.5 years [range 46-80];63% male;100% triple-class exposed;80% penta-drug exposed;77% triple-class refractory, 20% penta-drug refractory;30% prior BCMA-directed therapy;median follow-up [mF/U]: 7.5 mo [range 0.9-15.2]). 23 patients received 800 μg/kg Q2W (median 60.0 years [range 47-84];48% male;96% triple-class exposed;70% penta-drug exposed;65% triple-class refractory, 22% penta-drug refractory;17% prior BCMA-directed therapy;mF/U: 3.7 mo [range 0.0-12.0]). No treatment discontinuations due to AEs were reported at either RP2Ds. Most common AEs at the 405 μg/kg QW were CRS (73%;1 grade 3 CRS), neutropenia (67%;grade 3/4: 60%), and dysgeusia (60%;grade 2: 29%). Skin-related AEs occurred in 77% of patients and were all grade 1/2 (nail disorders: 30%). Infections occurred in 37% of patients (1 grade 3 COVID-19 pneumonia). Most common AEs at 800 μg/kg Q2W were CRS (78%;all grade 1/2), dry mouth (44%;all grade 1/2), and neutropenia (44%;grade 3/4: 35%). Skin-related AEs occurred in 65% of patients with grade 3 events in 13% (nail disorders: 17%). Infections occurred in 13% of patients (1 grade 3 pneumococcal sepsis). In 30 response-evaluable patients treated at 405 μg/kg QW, the overall response rate (ORR) was 70% (very good partial response or better [≥VGPR]: 57%). In 17 response-evaluable patients treated at 800 μg/ kg Q2W, the ORR was 71% (≥VGPR: 53%). Responses were durable and deepened over time with both RP2Ds (Figure). Median duration of response (DOR) was not reached at either RP2D;6-month DOR rate was 67% (95% CI: 41-84) at 405 μg/kg QW. Serum trough levels of talquetamab were comparable at both RP2Ds. Pharmacodynamic data at both RP2Ds showed peripheral T cell activation and induction of cytokines. SC talquetamab is well tolerated and highly effective at both RP2Ds. Preliminary data suggest that less frequent, higher doses of SC talquetamab do not negatively impact the safety profile. Further evaluation of talquetamab as monotherapy (phase 2;NCT04634552) and in combination with other therapies in patients with RRMM is underway. (Figure Presented) .

13.
Infectious Microbes and Diseases ; 4(1):26-33, 2022.
Article in English | Scopus | ID: covidwho-1806682

ABSTRACT

Hypoxic patients with coronavirus disease 2019 (COVID-19) are at high risk of adverse outcomes. Inhaled nitric oxide (iNO) has shown anti-viral and immunomodulatory effects in vitro. However, in vivo evidence of efficacy in hypoxic COVID-19 is sparse. This open label feasibility study was conducted at a single referral center in South India and evaluated the effectiveness of repurposed iNO in improving clinical outcomes in COVID-19 and its correlation with viral clearance. We recruited hypoxemic COVID-19 patients and allocated them into treatment (iNO) and control groups (1:1). Viral clearance on day 5 favored the treatment group (100% vs 72%, P < 0.01). The speed of viral clearance as adjudged by normalized longitudinal cycle threshold (Ct) values was positively impacted in the treatment group. The proportion of patients who attained clinical improvement, defined as a ≥2-point change on the World Health Organization ordinal scale, was higher in the iNO cohort (n = 11, 79%) as compared to the control group (n = 4, 36%) (odds ratio 6.42, 95% confidence interval 1.09-37.73, P = 0.032). The proportion of patients progressing to mechanical ventilation in the control group (4/11) was significantly higher than in the treatment group (0/14). The all-cause 28-day mortality was significantly different among the study arms, with 36% (4/11) of the patients dying in the control group while none died in the treatment group. The numbers needed to treat to prevent an additional poor outcome of death was estimated to be 2.8. Our study demonstrates the putative role of repurposed iNO in hypoxemic COVID-19 patients and calls for extended validation. Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

14.
Indian Journal of Clinical Biochemistry ; 36(SUPPL 1):S62, 2021.
Article in English | EMBASE | ID: covidwho-1767695

ABSTRACT

Validation of AG-Q COVID-19 N-Antigen Self- VTest in comparison with Real Time RT-PCR Ajaikumar Sukumaran, Arun Krishnan, Rhema Thomas, Jofy Paul, D M Vasudevan Introduction Currently, RT-PCR and the rapid antigen test (RAT) are the major stakeholders in COVID-19 diagnosis. The RTPCR is the gold standard testing method and RAT is considered for mass screening of COVID-19. In order to improve the accessibility and pace of diagnosis, ICMR had given permission for COVID-19 self-test by the public. AG-Q COVID-19 N-Antigen Self-Test kit is a home based rapid test kit developed by Agappe Diagnostics Limited. The kit has been validated at NIMS Medicity, Trivandrum and compared the performance with the RT-PCR Ct value. Aim Validation and comparison of AG-Q COVID-19 N-Antigen self-test with RT-PCR. Materials & Methods The AG-Q COVID19 N-Antigen self-test is a lateral flow immunochromatography based rapid test. The Covipath COVID-19 RT-PCR kit from ThermoFisher Scientific was used for the comparison study. A total of 72 subjects were recruited (30 positive & 42 negative subjects) for the study with the Institutional Ethical Committee approval and informed consent from the subjects. To perform the comparison study, a nasal swab sample in lysis buffe for RAT and a nasopharyngeal swab sample in VTM for RT-PCR were collected from each participants. Result The AG-Q COVID-19 N-Antigen self-test offers 100% specificity with sensitivity of 83.33%. Conclusion As per the study result, the AG-Q COVID-19 N-Antigen self-test is satisfying the ICMR recommended specificity and sensitivity for rapid antigen self-test as compared with the RT-PCR.

16.
National Journal of Community Medicine ; 12(12):439-443, 2021.
Article in English | Scopus | ID: covidwho-1614183

ABSTRACT

Introduction: To plan and implement effective control measures, knowledge about basic hygiene and the mechanism of disease transmission, and practices adopted in such circumstances is of utmost importance. Non-professional health care workers working in a tertiary care hospital is at a major risk than general population in contracting a pandemic. This study was undertaken to assess the awareness, attitude and practice during COVID-19 pandemic among non-health care workers in a tertiary care hospital. Materials and Methods: Cross-sectional self-administered questionnaire was used to assess the awareness, attitude and practice of non-health care workers. Personnel in pharmacy, patient service and food and security were taken as subjects. The subjects were also categorised according to their educational status. Results: The knowledge, attitude and practice scores and the total combined scores were found to be statistically significant based on the occupation and educational status of the subjects. Pharmacy personnel had better awareness and those with higher educational status were found to have favourable attitude and practice scores. Conclusion: The non-health care workers were found to have adequate knowledge, attitude and practice behaviour regarding prevention of Covid infection. Educational status of the subjects influenced their awareness, attitude and practice. © The Journal retains the copyrights of this article. However, reproduction is permissible with due acknowledgement of the source.

17.
Blood ; 138:158, 2021.
Article in English | EMBASE | ID: covidwho-1582394

ABSTRACT

Introduction: Despite recent advances in treatment, patients with multiple myeloma (MM) continue to relapse. G protein-coupled receptor family C group 5 member D (GPRC5D) is a promising target for immunotherapy in patients with MM due to its high expression in malignant plasma cells and limited expression in normal human tissue;unlike other antigens targeted by MM therapies, there is no indication that GPRC5D sheds into the periphery. Talquetamab (JNJ-64407564) is a first-in-class bispecific IgG4 antibody that redirects T cells to kill MM cells by binding to both GPRC5D and CD3 receptors. Here we report updated and new results of talquetamab at the recommended phase 2 doses (RP2Ds) from a phase 1 trial in relapsed/refractory MM (RRMM;NCT03399799). Methods: Eligible patients with MM had relapsed or refractory disease or were intolerant to standard therapies;patients previously treated with B-cell maturation antigen (BCMA)-directed therapies were eligible. This analysis focuses on patients who received talquetamab subcutaneously (SC;range 5.0-800 µg/kg) weekly or biweekly. Step-up dosing was used as a patient management strategy to minimize the severity of cytokine release syndrome (CRS). The primary objectives were to identify the RP2D (part 1) and assess talquetamab safety and tolerability at the RP2Ds (part 2). Adverse events (AEs) were graded by CTCAE v4.03 with CRS events graded per Lee et al 2014 criteria. Responses were investigator-assessed per International Myeloma Working Group criteria. Results: As of July 19, 2021, 95 patients have received SC talquetamab. The RP2D was originally identified as a weekly SC dose of 405 µg/kg talquetamab with step-up doses. However, alternative dosing schedules that require less frequent administration continue to be investigated. A biweekly RP2D was also identified as an SC dose of 800 µg/kg talquetamab with step-up doses. 30 patients received the 405 µg/kg weekly dosing schedule (median age: 61.5 years [range 46-80];63% male;100% triple-class exposed;80% penta-drug exposed;77% triple-class refractory, 20% penta-drug refractory;30% prior BCMA-directed therapy;median follow-up: 7.5 mo [range 0.9-15.2]). 23 patients received the 800 µg/kg biweekly dosing schedule (median age: 60.0 years [range 47-84];48% male;96% triple-class exposed;70% penta-drug exposed;65% triple-class refractory, 22% penta-drug refractory;17% prior BCMA-directed therapy;median follow-up 3.7 mo [range 0.0-12.0]). There were no treatment discontinuations due to AEs at either of the RP2Ds. The most common AEs at the 405 µg/kg weekly dose were CRS (73%;1 patient had grade 3 CRS), neutropenia (67%;grade 3/4: 60%), and dysgeusia (60%;grade 2: 29%);skin-related AEs occurred in 77% (all grade 1/2;nail disorders: 30%) of patients, and infections occurred in 37% of patients (1 patient had grade 3 COVID-19 pneumonia). The most common AEs at the 800 µg/kg biweekly dose were CRS (78%;all grade 1/2), dry mouth (44%;all grade 1/2), and neutropenia (44%;grade 3/4: 35%);skin-related AEs occurred in 65% of patients (grade 3: 13%;nail disorders: 17%) and infections occurred in 13% of patients (1 patient had grade 3 pneumococcal sepsis). In 30 response-evaluable patients treated with the 405 µg/kg weekly dose, the overall response rate (ORR) was 70% (very good partial response or better [≥VGPR] rate: 57%). In 17 response-evaluable patients treated with the 800 µg/kg biweekly dose, the ORR was 71% (≥VGPR rate: 53%). Responses were durable and deepened over time in both cohorts (Figure). Median duration of response (DOR) was not reached at either RP2D;the 6-month DOR rate for patients who received the 405 µg/kg weekly dose was 67% [95% CI: 41-84]. Serum trough levels of talquetamab were comparable at both RP2Ds. Consistent with the mechanism of action for talquetamab, pharmacodynamic data from cohorts treated at both dose levels showed peripheral T-cell activation and induction of cytokines. Conclusions: These findings indicate that SC talquetamab is well tolerated and highly effective at both RP2Ds. Preliminary data from the 800 µg/kg biweekly cohorts indicate that less frequent, higher doses of SC talquetamab do not have a negative impact on the previously described safety profile. Further investigation of talquetamab as monotherapy (phase 2;NCT04634552) and in combination with other therapies in patients with RRMM is underway. [Formula presented] Disclosures: Krishnan: MAGENTA: Consultancy;BMS: Consultancy, Current equity holder in publicly-traded company, Speakers Bureau;JANSSEN: Consultancy, Research Funding;City of Hope Cancer Center: Current Employment;REGENERON: Consultancy;SANOFI: Consultancy;GSK: Consultancy;Amgen: Speakers Bureau. Minnema: Celgene: Other: Travel expenses;Alnylam: Consultancy;Cilag: Consultancy;BMS: Consultancy;Janssen: Consultancy;Kite/Gilead: Consultancy. Berdeja: Lilly, Novartis: Research Funding;Abbvie, Acetylon, Amgen: Research Funding;Celularity, CRISPR Therapeutics: Research Funding;EMD Sorono, Genentech: Research Funding;Poseida, Sanofi, Teva: Research Funding;Bluebird bio, BMS, Celgene, CRISPR Therapeutics, Janssen, Kite Pharma, Legend Biotech, SecuraBio, Takeda: Consultancy;GSK, Ichnos Sciences, Incyte: Research Funding. Oriol: Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees;Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees;Oncopeptides: Consultancy, Membership on an entity's Board of Directors or advisory committees;GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees;BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees;Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. van de Donk: Roche: Consultancy;Takeda: Consultancy;Cellectis: Research Funding;Amgen: Consultancy, Research Funding;Janssen: Consultancy, Research Funding;BMS/Celgene: Consultancy, Honoraria;Novartis /bayer/servier: Consultancy. Rodriguez-Otero: Clínica Universidad de Navarra: Current Employment;Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees;Celgene-BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees;GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees;Pfizer: Consultancy;Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees;Kite: Honoraria, Membership on an entity's Board of Directors or advisory committees;Amgen: Honoraria;Regeneron: Honoraria. Askari: Janssen: Research Funding. Mateos: Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees;Sea-Gen: Honoraria, Membership on an entity's Board of Directors or advisory committees;Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees;Regeneron: Honoraria, Membership on an entity's Board of Directors or advisory committees;Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees;Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees;Celgene - Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees;Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees;Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees;Oncopeptides: Honoraria;Bluebird bio: Honoraria;AbbVie: Honoraria;GSK: Honoraria;Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees;Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees. Costa: BMS: Consultancy, Honoraria, Research Funding;Janssen: Consultancy, Honoraria, Research Funding;Amgen: Consultancy, Honoraria, Research Funding, Speakers Bureau;Karyopharm: Consultancy, Honoraria;Pfizer: Consultancy, Honoraria;Sanofi: Consultancy, Honoraria, Speakers Burea . Verona: Janssen: Current Employment. Ma: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Girgis: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Yang: Janssen: Current Employment. Hilder: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Russell: Janssen: Ended employment in the past 24 months. Goldberg: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Chari: Shattuck Labs: Consultancy, Membership on an entity's Board of Directors or advisory committees;Seattle Genetics: Membership on an entity's Board of Directors or advisory committees, Research Funding;Millenium/Takeda: Consultancy, Research Funding;Sanofi Genzyme: Consultancy, Membership on an entity's Board of Directors or advisory committees;Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees;BMS/Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding;Antengene: Consultancy, Membership on an entity's Board of Directors or advisory committees;Takeda: Consultancy, Research Funding;Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding;Pharmacyclics: Research Funding;Secura Bio: Consultancy, Membership on an entity's Board of Directors or advisory committees;Oncopeptides: Consultancy, Membership on an entity's Board of Directors or advisory committees;AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees;GlaxoSmithKline: Consultancy, Membership on an entity's Board of Directors or advisory committees;Novartis: Consultancy, Research Funding;Genentech: Consultancy, Membership on an entity's Board of Directors or advisorycommittees;Janssen Oncology: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding.

18.
Current Science ; 121(9):1147-1147, 2021.
Article in English | Web of Science | ID: covidwho-1535542
19.
2nd International Conference on Electronics and Sustainable Communication Systems, ICESC 2021 ; : 1074-1081, 2021.
Article in English | Scopus | ID: covidwho-1470301

ABSTRACT

The COVID-19 pandemic has increased the risk of contracting a deadly virus in public places such as malls, streets, or local shops. These essential places have proven to be hotspots for the dissemination of the coronavirus. One of the most efficient ways to curb the spread is to maintain social distancing. Currently, due to the lack of strict supervision, social distancing is not being followed. The paper provides a solution to implement a smart device meant to detect social distancing violations in public areas. The paper also compares three detection approaches, namely the You Only Look Once (YOLO) approach and its variants, the Histogram of Oriented Gradients - Support Vector Machine (HOG-SVM) approach, and the top view camera angle approach to detect these violations. The most practical approach, i.e., the YOLOv3-tiny, was loaded onto the Raspberry Pi to make a fully automated device. The paper also addresses the design flow, the working of the different approaches, and the future scope in advancements. © 2021 IEEE.

20.
Journal of the Neurological Sciences ; 429, 2021.
Article in English | EMBASE | ID: covidwho-1466684

ABSTRACT

Background and aims: We conducted TOP-PRO-study, a double-blind RCT, to know whether propranolol is as efficacious as topiramate for the prevention of CM. In this paper, we report the secondary efficacy outcomes. Primary efficacy outcome showing the non-inferiority of propranolol have been described in another paper. Methods: CM patients aged above 18 years and less than 65 years of age, not on any preventive treatment were randomly allocated to receive topiramate (100 mg/day) or propranolol (160 mg/day). Secondary outcomes were mean change per 28 days at the end of 24 weeks compared to baseline in headache days, acute migraine treatment (AMT) days, visual analog scale (VAS) scores, headache impact-6 (HIT-6) scores, migraine specific quality of life (MSQOL) score and achievement of more than 50% reduction in headache days. Results: COVID-19 pandemic and lockdown halted the recruitment before the trial reached the planned sample size of 244. Of the 175 randomized patients, 95 (topiramate 46 and propranolol 49) completed the trial. The two groups were matched in terms of age, sex and baseline headache parameters. At the end of 24 weeks, both groups showed similar mean improvements in headache days per 28 days (−7.7 vs −7.8;p = 0.928), >50% responder rate (32.6% vs 34.7%), AMT days (−6.7 vs −7.0;p = 0.835), VAS score (−1.7 vs −2.2;p = 0.355), HIT-6 score (−5.2 vs −7.3;p = 0.153), MSQOL score (−5.8 vs −9.3;p = 0.098). Conclusions: Propranolol was as efficacious as topiramate for the prevention of CM as assessed by multiple secondary outcome parameters. (Academic study: Clinical Trials Registry-India CTRI/2019/05/018997).

SELECTION OF CITATIONS
SEARCH DETAIL